Search PubMedSearch

Biomedical subjects

M A Powell

Publications and source records attributed to M A Powell.

18 recordsLinked to original sources

Need for and provision of general practice in London.

This study examines the spatial distribution of general practice in London, taking into account both practice and population characteristics. While need for general practice is higher in inner London, some areas of outer London experience high levels of need. Inner London tends to have a greater quantity but lower quality of general practice. However, as in the case of the needs indices, this situation cannot be described as a simple inner city/outer city dichotomy. It is concluded that not all inner London areas suffer from high need and poor general practice and not all outer London areas have low need and good general practice.

Catchment Area, Health

Regulation of calpactin I phospholipid binding by calpactin I light-chain binding and phosphorylation by p60v-src.

Calpactins I and II are proteins that bind Ca2+, phospholipids, actin and spectrin; they are also major substrates of oncogene and growth-factor-receptor tyrosine kinases. Since calpactins have been proposed to provide a link between membrane lipids and the cytoskeleton, we examined in detail the interactions between purified calpactin I and phospholipid liposomes. We focused on the Ca2+-dependence, the effects of phosphorylation of calpactin I by p60v-src (the protein kinase coded for by the Rous-sarcoma-virus oncogene), and the effects of the binding of calpactin I light chain to calpactin I heavy chain. Binding of the light chain to the heavy chain increased the affinity of calpactin I for phosphatidylserine (PS) liposomes. The opposite effect was observed for phosphorylation by p60v-src; phosphorylation decreased the affinity of calpactin I for PS liposomes. These two opposite effects appeared to be independent, since phosphorylation did not prevent light-chain binding to the heavy chain. Calpactin I was found, by the use of three different techniques, to bind to phospholipid liposomes at less than 10(-8) M free Ca2+. This result is in contrast with those of previous studies, which indicated that greater than 10(-6) M free Ca2+ was required. Our findings suggest that calpactin I may be bound to phospholipids in vivo at Ca2+ concentrations of about 1.5 x 10(-7) M, typical of resting unstimulated cells, and that this interaction may be modulated by light-chain binding and phosphorylation by p60v-src.

Annexins

Calpactins: two distinct Ca++-regulated phospholipid- and actin-binding proteins isolated from lung and placenta.

Three forms of calpactin, the 36,000 Mr Ca++-binding cytoskeletal protein, were isolated in large amounts from bovine lung and human placenta using cycles of calcium-dependent precipitation followed by solubilization with EGTA-containing buffers. Calpactin-I as a tetramer of heavy (36 kD) and light (11 kD) chains was the predominant form of calpactin isolated, however milligram amounts of the calpactin-I heavy chain monomer and calpactin-II, a related but distinct molecule, were also isolated by this method. Calpactin-II was characterized in some detail and found to bind two Ca++ ions with Kd's of 10 microM in the presence of phosphatidylserine. Both calpactin-I and -II were found to aggregate liposomes at micromolar Ca++ concentrations, suggesting that at least two phospholipid-binding sites are present on these molecules. Both calpactin monomers bind to and bundle actin filament at high (1 mM) but not low (less than 1 microM) Ca++ concentrations. Amino-terminal sequence analysis of a lower molecular mass variant of calpactin-II revealed that this protein was the previously identified human "lipocortin" molecule. Antibodies were elicited to calpactin-I and -II and the cell and subcellular distribution of each was compared. Calpactin-II was only present at high levels in tissues (lung, placenta) which contained high levels of calpactin-I. Other tissues (intestine) contained high calpactin-I and undetectable levels of calpactin-II. Double-label immunofluorescence microscopy on human fibroblasts revealed that, like calpactin-I, calpactin-II is present in a submembraneous reticular network, although the distribution of the two calpactins is not identical.

Actins

Territorial justice and primary health care: an example from London.

This paper is part of a larger piece of research which examines the spatial relationship between need for and provision of primary health care in London. The research reported here is concerned with empirically testing the 'inverse care law' at the DHA level. One concept that may be used to guide this analysis is 'territorial justice'. Several conceptual problems associated with the use of territorial justice are outlined. These include inadequate conceptualisation of the form of social justice assumed, of the problem of deriving need indices and of the nature of resources. A final problem is concerned with the spatial scale of the analysis. The concept of territorial justice is made operational so as to identify relatively under and overprovided DHAs. The result is that the often held assumption of a simple dichotomy of relatively underprovided inner DHAs and overprovided outer DHAs is shown not to be tenable. However, this research concentrates on the quantity of care, and does not focus on the important aspect of its quality. This preliminary analysis reveals the need for further research on this important topic.

Delivery of Health Care

Cholesteatoma.

Explore the source record for details and available documents.

Cholesteatoma

Candida pharyngitis.

Explore the source record for details and available documents.

Antifungal Agents

Polymyalgia rheumatica.

Explore the source record for details and available documents.

Diagnosis, Differential

A new look at pharmacologic therapy for adult asthma.

Antiinflammatory agents in conjunction with beta agonists in the form of inhaler cromolyn or steroids are currently the cornerstone of therapy for recurrent asthma after the patient has failed on beta agonists alone. Early treatment with antiinflammatory agents is strongly recommended, and may prevent irreversible airflow obstruction caused by chronic inflammation, reducing the mortality from this illness.

Asthma